Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 April 2015Website:
http://zevra.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 26 Jun 2024 20:00:23 GMTDividend
Analysts recommendations
Institutional Ownership
ZVRA Latest News
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog
Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
CELEBRATION, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference being held virtually on April 8-9, 2024. The Company's presentation will take place on Monday, April 8, 2024, at 3:45 p.m. ET. Additionally, members of Zevra's management team will be available for one-on-one investor meetings with registered attendees throughout the conference.
Zevra Therapeutics, Inc. (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Neil McFarlane - President and Chief Executive Officer Christal Mickle - Co-Founder and Chief Product Development Officer LaDuane Clifton - Chief Financial Officer, Secretary and Treasurer Joshua Schafer - Chief Commercial Officer and Executive Vice President, Business Development Conference Call Participants Louise Chen - Cantor Fitzgerald Jonathan Aschoff - ROTH MKM Sumant Kulkarni - Canaccord Oren Livnat - H.C. Wainwright Operator Good morning, everyone.
CELEBRATION, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET, to review its corporate and financial results for the third quarter of 2023.
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs
Zevra's acquisition of Acer Therapeutics adds significant value to its rare disease-focused strategy. Acer's newly launched product, Olpruva, aligns with Zevra's potential commercial efforts with arimoclomol in targeting rare diseases. Acer's Phase 3 trial for vascular Ehlers-Danlos syndrome fills an unmet need in the market and adds to Zevra's late-stage pipeline.
The consensus price target hints at a 248.5% upside potential for Zevra Therapeutics (ZVRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What type of business is Zevra Therapeutics?
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
What sector is Zevra Therapeutics in?
Zevra Therapeutics is in the Healthcare sector
What industry is Zevra Therapeutics in?
Zevra Therapeutics is in the Biotechnology industry
What country is Zevra Therapeutics from?
Zevra Therapeutics is headquartered in United States
When did Zevra Therapeutics go public?
Zevra Therapeutics initial public offering (IPO) was on 16 April 2015
What is Zevra Therapeutics website?
https://zevra.com
Is Zevra Therapeutics in the S&P 500?
No, Zevra Therapeutics is not included in the S&P 500 index
Is Zevra Therapeutics in the NASDAQ 100?
No, Zevra Therapeutics is not included in the NASDAQ 100 index
Is Zevra Therapeutics in the Dow Jones?
No, Zevra Therapeutics is not included in the Dow Jones index
When does Zevra Therapeutics report earnings?
The next expected earnings date for Zevra Therapeutics is 14 August 2024